Nagy áttörés történt a gyermekkori agydaganat gyógyszerfejlesztésében. A gyermekkori agydaganatok gyakoribb rosszindulatú betegség a gyermekek körében. A legújabb kutatások kimutatták, hogy egy új koktél gyógyszer képes kezelni a gyakori gyermekkori agydaganatokat.
Cancer Cell” magazine recently announced that in the UK, about 400 children develop brain tumorok each year, of which the prevalence of boys is slightly higher than that of girls.
Are we able to take advantage of the results of tumor gene testing and tailor-made treatments, a strategy often referred to as personalized medicine? This treatment strategy can produce very good results for patients with brain tumors.
Neural myeloblastoma (medulloblastoma) is one of the most common rosszindulatú daganatok of the cerebellum. This agytumor grows rapidly and most often occurs in children around the age of 5. A kezelés lehetőségei include surgery, radiation, and chemotherapy. Although great progress has been made in treatment methods and techniques, the success rate of treating myeloblastoma still lags far behind other children’s malignancies. In particular, myeloblastoma is a highly aggressive malignancy. Only 40% of patients with medulloblasztóma survive, compared with other tumors of a less severe type-with a survival rate of more than 80%.
Researchers in the United States have discovered a new combination therapy for the treatment of highly aggressive neuroblasztóma. In laboratory tests, the drug killed rák cells without any toxicity to normal cells, and researchers hope to conduct clinical trials of the drug. Robert Wechsler-Reya, an adjunct professor at the Sanford Burnham Prebys Medical Institute, said: “Our goal is to confirm that the drug has low toxicity properties. Because doctors and patients in this case urgently require new clinical treatment options, we will soon apply the drug from the laboratory to clinical treatment.
Más gyógyszerekkel kombinálva új tumorokat gátló vegyületeket in vitro és in vivo szűrnek.
Klinikai vizsgálatok for neuroblastoma are often very challenging because of the limited number of patients. In addition, coupled with the variability of the disease, most treatments are only effective for one subtype of patient. Understanding which patients will respond to this treatment is one of the main goals of the trial.
"Ha testre szabott kezeléseket tudunk kifejleszteni tumor gének alapján - ez a stratégia, amelyet általában individualizált kezelésnek neveznek -, ez hatalmas evangéliumot hozhat bizonyos daganatokban szenvedő betegek számára."
A neuroblasztómának négy különféle típusa van, és a daganatok harmadik csoportjával rendelkező betegek prognózisa a legrosszabb - a betegek csak 40% -a él túl hosszú távon. Ezzel szemben a többi neuroblasztóma hosszú távú túlélése viszonylag optimista, és a betegek körülbelül 80% -a képes hosszú távon túlélni.
A neuroblasztómában szenvedő betegek harmadik csoportjának többségében magas a MYC onkogén expressziója, ami az ellenőrizetlen sejtosztódás és a daganatok kialakulásának oka.
There was a study on mice with a third type of neural tube cell tumors that showed histone deacetylase inhibitors (HDACIs) and phosphatidylinositol 3-kinase inhibitors (PI3KIs) might stop mice and people from making neurotubular glioblastomas without doing too much damage to normal cells.
We found several histone deacetylase inhibitors that can kill MYC oncogene-activated neural tube cell tumors without harming normal cell agents (HDACIs),” said Pei Yanxin, an assistant professor at the National Children’s Medical Center Washington, DC
The most effective of these compounds is panobinostat, which has entered clinical trials in other típusú rák, but has not yet been tested on neuroblastoma.” Dr. Kun-Wei, a postdoctoral researcher at Stanford University, added: “Several other studies have revealed that the mechanism of action of panobinostat is to promote the activation of the FOXO1 gene that can interfere with the oncogenes of MYC.
Phosphatidylinositol 3-kinase inhibitors (PI3KIs) are also thought to have the effect of activating the FOXO1 gene. We hypothesized that panobinostat and phosphatidylinositol 3-kinase inhibitors (PI3KIs) could work together to block Rák sejt túlélés.
“It is true that the combined treatment of these two drugs can significantly increase the survival of patients with tumors carrying the MYC gene compared to using a single drug alone.”
